Journal of Pharmaceutics & Drug Delivery Research ISSN: 2325-9604

Reach Us +1 209 730 0872
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Pharm Drug Deliv Res Vol: 6 Issue: 1

Indian Propolis Loaded Folic Acid Conjugated PLGA Nanoparticles: Formulation Development, Characterization, In Vitro and In Vivo Anticancer Study

Harshad S Kapare1, Sathiyanarayanan L2*, Arulmozhi S3 and Mahadik KR2
1Department of Quality Assurance Techniques, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, India
2Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, India
3Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, India
Corresponding author : Dr. Sathiyanarayanan L
Associate Professor, Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune 411038, Maharashtra, India
Tel:
+91 9371085066, 020 25437237
Fax: 020 25439383
E-mail:
[email protected]
Received: March 20, 2017 Accepted: April 12, 2017 Published: April 17, 2017
Citation: Kapare HS, Sathiyanarayanan L, Mahadik KR, Arulmozhi S (2017) Indian Propolis Loaded Folic Acid Conjugated PLGA Nanoparticles: Formulation Development, Characterization, In Vitro and In Vivo Anticancer Study. J Pharm Drug Deliv Res 6:1. doi: 10.4172/2325-9604.1000164

Abstract

Propolis, a natural bee hive product is well proven for its anticancer potential due its various polyphenols and flavonoids constituents. Anticancer efficacy of propolis is limited due to its poor water solubility and bioavailability. The present study is investigated for design and development of ethanolic extract of Indian propolis (EEIP) loaded folic acid conjugated Poly (D,L-lactide-co-glycolide) nanoparticles (denoted as ELFPN) were investigated to achieve improved solubility, sustained drug release and to study synergized anticancer efficacy. Formulation development, characterization and optimization were carried out by design of experiment approach. . In vitro and in vivo cytotoxicity study was carried out for optimized formulation. Developed ELFPN showed the particle size and encapsulation efficiency 178 ± 5 - 205 ± 5 nm and 73.16 ± 1.89 - 76.37 ± 1.89 respectively. Optimized formulation showed sustained drug release over a period of 48 h with no sign of blood toxicity. Moreover, concentration of the drug needed for growth inhibition of 50 % of cells in a designed time period (GI50) was decreased by 43.34 %, for ELFPN as compared to EEIP in human breast cancer MCF-7 cells indicating targeting with synergistic effect of ELFPN. An improved anticancer effect was reflected in in-vivo Daltons Ascites Lymphoma model by reducing tumor cells count. The developed ELFPN showed improved in vitro cytotoxic effect, in-vivo anti-cancer activity with desirable characteristics for nanoparticle formulation thus can be useful for biomedical applications.

Keywords: Indian propolis; Formulation; Nanoparticles; PLGA; Conjugation; Factorial design; Cancer

Track Your Manuscript

Share This Page